Taxanes in adjuvant and neoadjuvant therapy for breast cancer
Taxanes (paclitaxel and docetaxel) are currently considered to be basic cytostatics in the treatment of all breast cancer (BC) stages. The results of conducted and ongoing clinical trials suggest that incorporation of taxanes into adjuvant and neoadjuvant chemotherapy regimens enhances the efficienc...
Saved in:
| Main Author: | S. V. Limareva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-08-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/263 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary
by: A. G. Manikhas, et al.
Published: (2016-09-01) -
Choice of adjuvant drug therapy on the basis of the molecular classification of breast cancer
by: N. S. Besova
Published: (2014-07-01) -
Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer—a retrospective cohort study
by: Árpád Kézdi, et al.
Published: (2025-04-01) -
Adjuvant chemotherapy for stage II and III gastric adenocarcinoma: A retrospective analysis with long-term follow-up
by: Hsiu-Tzu Wang, et al.
Published: (2025-04-01) -
CNA landscape of HER2-negative breast cancer during administration of taxane-containing schemes of neoadjuvant chemotherapy
by: M. K. Ibragimova, et al.
Published: (2025-04-01)